Biotech Analysts Watsek & Schimmer discuss conclusions from LLY‘s EMBER-3 Study and its implications for ARVN‘s VERITAC-2 Trial; results from ARVN’s TACTIVE-U Ph1; takeaways from BCYC‘s zelenectide pevedotin data and RLAY‘s RLY-2608 and OKUR‘s OKI-219 on an Analyst/Industry conference call to be held on December 13 at 12 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- eBay downgraded, GM upgraded: Wall Street’s top analyst calls
- Eli Lilly reinstated with a Buy at BofA
- Eli Lilly to present Phase 3 results for Jaypirca at ASH meeting
- Eli Lilly announces $15B share repurchase program, 15% dividend increase
- M&A News: European Regulators Approve Novo Holdings’ Acquisition of Catalent (CTLT)